Cardiac assessment of early breast cancer patients 18years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines

“…Both paediatric and adult survivors of anthracycline‐based chemotherapy have a lifelong risk for the development of LV dysfunction and HF ,. The time lapse between treatment and the development of HF can be very long (>10 years) . Thus, even in asymptomatic patients treated with cardiotoxic therapy, particularly anthracyclines, LV dysfunction and HF can potentially occur.…”

Long‐term effect of epirubicin on incidence of heart failure in women with breast cancer: insight from a randomized clinical trial

“…The study reported after 16 years of follow-up a proportion of HF of 5.5% in the high-dose regime. 16 This finding is, however, not unambiguous, since follow-up was not complete and the majority of HF cases also received left-sided radiotherapy, 17 which is a well-established risk factor for cardiac disease in general and particularly for ischaemic and valvular heart disease with the radiotherapy method used in the period of time of the trial. 18 In our study no correlation with HF and left-sided radiotherapy was found.…”

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines

“…Czas od leczenia do wystąpienia HF może być bardzo długi (> 10 lat) [300]. Dlatego też nawet u bezobjawowych pacjentów poddanych leczeniu kardiotoksycznemu, zwłaszcza antracyklinami, mogą wystąpić dysfunkcja LV i HF.…”